Carisma Therapeutics is a biotechnology company that is disrupting cancer treatment norms by leveraging the natural power of monocytes and macrophages to engineer them to attack tumors. They are pioneering the development of CAR-Macrophages, a unique therapeutic approach to immunotherapy that addresses the challenges faced by current cell therapies. Their pipeline includes multiple CAR-Macrophages designed to target solid tumors and they are dedicated to innovating in the field of cell therapy.

Carisma Therapeutics

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Carisma Therapeutics, Inc.

Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.

Livzon Pharmaceutical Group

Solasta Ventures

SymBiosis LLC

Wellington Partners

Penn Medicine Co-Investment Program

HealthCap

IP Group

4BIO Capital

AbbVie Biotech Ventures

Agent Capital

Pictet Alternative Advisors

AbbVie

At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality:
•	Testing and validating our foundational scientific perspective
•	Redefining manufacturing
•	Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships

Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform: https://bit.ly/39dHRwm

New data from our landmark clinical trial of CT-0508 were presented for the very first time at #SITC22 and we are encouraged by the evidence that CAR-M therapy is feasible and generally well-tolerated by patients. Also shared were early pre-clinical data on CT-1119 demonstrating control tumor growth in pre-clinical lung cancer models as well as preliminary insights from a novel immunotherapy platform. Learn more about the seven abstracts accepted & important info here:

Announced Today: Abstract for oral presentation of clinical data from CT-0508 trial, four pre-clinical study abstracts and one clinical trial design abstract accepted at #SITC22. Register on the SITC website to view our presentation and posters. Important information here: https://lnkd.in/eUYJkFqr

We are thrilled to announce that Carisma and Sesen Bio have entered into a definitive merger agreement and, upon closing, expect the combined company to operate under the Carisma name and trade on the Nasdaq Capital Market. We anticipate this transaction will put us in a strong financial position to continue developing our lead candidate CT-0508 and unlock the potential value of CAR-Macrophages for patients.

It’s been nearly a decade since our Chief Scientific Officer, Michael Klichinsky, discovered a new method of genetically modifying patients’ own immune cells – called macrophages – to destroy solid tumor cancer cells while generally sparing normal tissue. This discovery led to the formation of Carisma Therapeutics back in 2016. Since then, we’ve continued to evaluate and develop the potential for using engineered macrophages to treat cancer and other serious disorders. We believe this transaction will further fuel our efforts, and we’re looking forward to the bright future ahead.
 
Important information here: https://lnkd.in/eeJ57ggj

Interested in a career at Carisma? Open positions are listed on our website or can be found through reputable recruiters. If you are looking for more information or are interested in open positions, please visit: https://lnkd.in/ekWu4hu

Thanks to everyone who joined our live webcast where we discussed the latest patient data from our landmark first-in-human Phase 1 clinical trial CT-0508 and our progress toward developing a first-of-its-kind immunotherapy for patients with hard-to-treat cancers. To catch up on what you missed visit: https://carismatx.com/

Our Co-Founder and Chief Scientific Officer, Michael Klichinsky, is presenting on a panel at Stifel Financial Corp.'s Virtual Cell Therapy Summit where he will give the latest update on the CT-0508 clinical trial for our first-in-human study of CAR-Macrophages for the treatment of HER2 overexpressing solid tumors. Register and tune in here: https://lnkd.in/gfgmzHpx

We are thrilled to announce that our CEO, Steven Kelly, has been named EY’s Greater Philadelphia Entrepreneur of the Year. We are grateful for Steve’s leadership in guiding us toward game-changing therapeutic innovations while navigating strategic company growth and applaud him for this latest achievement! Congratulations to Steve! #EOYGP https://lnkd.in/gC6fUPq3

Join us TOMORROW for a deep dive presentation and discussion surrounding the first-in-human study of CAR-Macrophages for the treatment of HER2 overexpressing solid tumors. Our landmark study of CT-0508 is open for enrollment and was the first of the engineered myeloid cell platform, which has the potential to transform the treatment of hard-to-treat cancers. Register now for our upcoming webcast to learn more about our CAR-M platform and the latest clinical trial data: https://bit.ly/39dHRwm

COM:CARISMATX

Carisma Therapeutics

Last Close

1.09

30/08 20:00

Market Cap

47.77M

Beta: -

Volume Today

77.63K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

Metrics